Articles Archives - Page 273 of 714

WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

WednesdayApr 13, 2022 9:30 am

O’Cannabiz Conference Expo & Awards Offering A Confluence Of Cannabis Industries

Cannabis enthusiasts, traders, cultivators and allied industries are invited to attend the O’Cannabis Expo & Awards from June 1-3, 2022 In Toronto, Canada. After the last year’s rescheduling, the O’Cannabis Conference is back this year for a physical 3-day event. The team is grateful to the exhibitors, sponsors, partners as well as pre-purchased ticket holders for their patience and trust. The event venue is the International Centre Hall #5, Toronto, Canada, a hub of business and consumer exhibitions in Canada. O’Cannabiz is a leading company engaged in organizing national high-profile events, to foster global connections between business houses and the…

WednesdayApr 13, 2022 9:15 am

GreenBox POS (NASDAQ: GBOX) Releases Fourth Quarter and Full Year 2021 Results

On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021 Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020 The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues The financial figures were accompanied by a corporate update and expected prospects for 2022. On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that…

WednesdayApr 13, 2022 9:15 am

InnerScope Hearing Technologies Inc. (INND) Ends 2021 on Right Foot, Set for a Dominant 2022

Over 31 million Americans have hearing loss but don’t utilize a hearing aid, primarily due to prohibitively high costs In the last 5 years, U.S. Presidents and Congress has demonstrated a strong commitment to making hearing aids affordable to all, including pressure on the FDA to complete changes now InnerScope has aggressively grown its business model through two key acquisitions and new sales channels that should lend to significant revenue growth as new regulations are put in place More than 38 million Americans have some degree of hearing loss. Sadly, due mostly to prohibitively high costs, only about 20% of…

WednesdayApr 13, 2022 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there The study…

TuesdayApr 12, 2022 9:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients) Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need…

TuesdayApr 12, 2022 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa) The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion…

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

TuesdayApr 12, 2022 9:00 am

Advanced Container Technologies Inc. (ACTX) Makes Mark at CannaCon Conference, Strengthens Foothold in Growing Market

The company exhibited at the premier event, held March 31–April 1, 2022 ACT has worked to strengthen its presence in the cannabis space This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026 Advanced Container Technologies (OTC: ACTX) recently wrapped up a successful appearance at the CannaCon Conference, showcasing its new product line and strengthening brand awareness. The company exhibited at the premier event, held March 31–April 1, 2022, alongside Grassfire Distro, ACT’s exclusive packaging reseller (https://ibn.fm/WqmI3). Prior to the two-day event, Advanced Container Technologies CEO Doug Heldoorn noted that ACT had…

Site Search

Company Search

Category: Articles